Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) – Pipeline Review, H2 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)

The report reviews Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects

The report assesses Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Ablynx NV

Amgen Inc

Apogenix GmbH

Bristol-Myers Squibb Company

Five Prime Therapeutics Inc

Incyte Corp

MedImmune LLC

Merck & Co Inc

Novartis AG

OncoMed Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) Overview 8

Therapeutics Development 9

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Stage of Development 9

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Therapy Area 10

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Indication 11

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Companies 14

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 20

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development 22

Ablynx NV 22

Amgen Inc 23

Apogenix GmbH 24

Bristol-Myers Squibb Company 25

Five Prime Therapeutics Inc 26

Incyte Corp 27

MedImmune LLC 28

Merck & Co Inc 29

Novartis AG 30

OncoMed Pharmaceuticals Inc 31

Regeneron Pharmaceuticals Inc 32

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles 33

AMG-228 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

BMS-986156 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

FPA-154 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

GWN-323 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

INCAGN-1876 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

LKZ-145 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MEDI-1873 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MK-1248 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

MK-4166 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Monoclonal Antibodies to Agonize GITR for Immunology and Oncology - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Monoclonal Antibody to Agonize GITR for Hematological Malignacies and Solid Tumors - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Monoclonal Antibody to Agonize GITR for Oncology - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Monoclonal Antibody to Agonize GITR for Oncology - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Recombinant Protein to Agonize GITR for Solid Tumor - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

TRX-518 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Featured News & Press Releases 50

Nov 12, 2016: Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist 50

Nov 11, 2016: Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting Demonstrating Potent Anti-Tumor Activity with Novel Tetravalent Anti-GITR Antibody 50

Nov 03, 2016: Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting For Novel Tetravalent Anti-GITR Antibody 51

Jun 22, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors 51

Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting 52

Apr 19, 2016: OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016 52

Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 53

Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody 54

Sep 16, 2015: OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference 54

Apr 05, 2011: Tolerx Presents Preclinical Data On New Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses 55

Feb 09, 2011: Tolerx Presents Preclinical Data On TRX518 56

Dec 14, 2010: Tolerx Initiates Phase I Clinical Trial Of TRX518 For Treatment Of Cancer 57

Dec 01, 2010: Tolerx And Cancer Research Institute Enter Collaboration To Accelerate Development Of TRX518 58

Jun 25, 2010: Tolerx Reports Preclinical Data On TRX518 For Treatment Of Cancer 59

Oct 21, 2008: Laureate To Manufacture Tolerx’s TRX518 Antibody 60

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Ablynx NV, H2 2016 22

Pipeline by Amgen Inc, H2 2016 23

Pipeline by Apogenix GmbH, H2 2016 24

Pipeline by Bristol-Myers Squibb Company, H2 2016 25

Pipeline by Five Prime Therapeutics Inc, H2 2016 26

Pipeline by Incyte Corp, H2 2016 27

Pipeline by MedImmune LLC, H2 2016 28

Pipeline by Merck & Co Inc, H2 2016 29

Pipeline by Novartis AG, H2 2016 30

Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 31

Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 32

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports